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ABSTRACT: 
Aim : 
  Audiologic monitoring and renal function monitoring for Drug 
Resistant patients under  programmatic management of drug resistant 
tuberculosis reatment  for six to nine months period in Tirunelveli 
Medical College Hospital DR-TB UNIT, from January  2014 to 
December 2014.   
MATERIALS AND METHODS; 
Total of 152 newly diagnosed DR-TB patients those registered in DR-
TB centre , Tirunelveli medical college hospital   from January 2014 to 
December 2014 were screened.  
 INCLUSION CRITERIA 
 All newly diagnosed (n- 51) DR-TB patients  with normal 
baseline audiometry    and normal serum urea and creatinine levels were 
included in this study    
RESULTS: 
1. In  this prospective observational study, during the intensive 
phase of CATEGORY IV regimen  43.3% patients  developed 
statistically significant OTOTOXICITY , 2% patients 
developed  NEPHROTOXICITY and 2% of patients 
developed BOTH OTOTOXICITY AND 
NEPHROTOXICITY.  
 
2. OTOTOXICITY-  63.63% patients   developed bilateral 
hearing loss  and 36.36% patients developed unilateral 
hearing loss. among the patients with ototoxicity  75%  
patients   had  mild hearing loss, and  mostly  during first 
three months period  of the  intensive phase.  
 
3. In our study  64% patients with hearing loss are asymptomatic 
and 36% patients noticed symptoms associated with hearing 
loss 
CONCLUSION: 
 In our  study 64 % of asymptomatic hearing loss cases were picked 
up by using pure tone audiometry. Early detection of the hearing loss 
among   these patients shall improve  adherence to the treatment.  
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INTRODUCTION 
Revised National Tuberculosis Control Programme (RNTCP) for 
tuberculosis treatment was   started in India from the year 1997. PMDT  
services  ( Programmatic  Management  of  Drug resistant   Tuberculosis  )  in 
our country  was  started in the year  2000.  PMDT covers all newly diagnosed 
Drug resistant tuberculosis which include programme based drug resistant 
tuberculosis diagnosis, and management.  Newly diagnosed DR-TB patients are 
admitted in DR-TB units for initiation of CATEGORY IV regimen. DOTS 
PLUS (CATEGORY IV) regimen is given for a period of 24  months . 
 During   intensive  phase,  injection  Kanamycin,  Levofloxacin,  
Ethionamide,  Ethambutol,  Cycloserine,  Pyrazinamide is  given  for  a  period  
of  six  to  nine  months . In the continuation phase,  Levofloxacin,  
Ethionamide,  Ethambutol,  Cycloserine  is given for  the  next  18  months  
period. In the  treatment of  drug  resistant tuberculosis , above  mentioned  
second  line  drugs  are  associated  with significant adverse  effects which 
leads to permanent disability.    Inj Kanamycin (15 -20 mg/kg) given as an 
Intramuscular injection daily for six days/week.  Inj.kanamycin produces well 
documented ototoxicity and renal toxicity. Early  detection of  these adverse  
effects and  their correction  will  improve  the  adherence  to  the  treatment,  
and  prevent  permanent  hearing loss.   
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Ototoxicity presents with   hearing impairment   or vestibular symptoms.  
Hearing dirsturbances in the form of hard of hearing, fullness in the ear and 
tinnitus. Hearing loss may be unilateral or bilateral.  
      Kanamycin induced ototoxicity initially involves higher frequencies then 
slowly progresses to lower frequencies, later it involves speech frequencies 
also. Vestibular symptoms like tinnitus, vertigo, giddiness, ataxia, nystagmus 
may be noticed by the patient taking inj .Kanamycin.  
Kanamycin attains high concentration in the renal cortex, and its toxicity 
is directly related to the total amount of drug received by the patients. 
Aminoglycoside induced nephrotoxicity is reversible. Patients with renal failure 
leads to high blood plasma levels of kanamycin, excess drug is concentrated in 
labyrinthine fluid which directly destroys the hair cells in the cochlea. 
In DR-TB patients periodic audiometry tests,monitoring of  blood urea 
and serum creatinine levels  is important to detect the adverse effects earlier 
and avoid the drug induced ototoxicity and nephrotoxicity.     
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2. MDR-TB / Category IV Regimen 
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Tuberculosis  is one of the most common infectious diseases in the 
world  responsible  for  more  than   nine  million  new  cases, two million 
deaths  per year 1 . India is  the  country  with  the  highest  burden  of  TB.  
World  Health  Organization     statistics  for  2013  gives  an  estimated 
new cases of  2.1  million  cases  of  TB  for  India  out  of  a  global  
incidence  of nine million new cases .  The  estimated  TB  prevalence in 
the year 2013  is  2.6  million .  It  is   about  40 %  of  the  Indian   
population  is infected  with  TB  bacilli , most of them  have  latent TB  . 
In our country TB  treatment   after defaulters   are    high about (30%) ,  
which  leads  to  MDR – TB 2.  
Giovanni Miglio ,TB expert says, “Resistance  is  man – 
made,caused  by  exposure  to  the  wrong  treatment , the  wrong  
regimen  ,  the  wrong  treatment  duration” . A  comprehensive  approach  
to  early detection ,  appropriate  management  and  public  health  
measures  needs  to  be applied  worldwide  to  cure  TB  patients  and  
prevent  further  transmission  of the  disease to the community 3. 
 In the year 1998, CATEGORY IV regimen or DOTS PLUS regimen was 
included in the DOTS programme, in order  to treat the patient and control 
the spread of DR TB bacilli transmission in the community. DR TB cases 
confirmed with laboratory investigation done in RNTCP accredited 
laboratory  is  accepted for initiating the CATEGORY IV regimen. 
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         Definition for MDR-TB : 
 Tubercle bacilli  that is  resistant to at least the two most potent first line 
anti tuberculosis drug H (isoniazid) and R (rifampicin) .  
Definition for XDR-TB : 
 Tubercle bacilli  that is  resistant to INH and  Rifampicin and any 
one of the fluoroquinolones , and resistant to atleast one of the injectable 
second line drugs like capreomycin, kanamycin, and amikacin . 
           Primary  MDR TB: 
             Presence of resistant strain of  mycobacterium tuberculosis in a 
patient newly diagnosed with TB who has not been previously treated 
with TB drugs or treated with TB drugs for less than one month duration. 
Acquired MDR-TB: 
           Presense of a resistant strain in a TB patient who has previously  
received at least one month of  anti TB treatment. 
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Mono-resistance: 
            Tubercle bacilli that is resistant to one of the first line anti-TB 
drug in an RNTCP accredited laboratory. 
  Poly-resistance:  
          Tubercle bacilli that is resistant to more than one first line anti TB 
drugs, other than isoniazid and rifampicin 
The prevalence of drug resistant TB ( DR-TB) is  very low in most parts 
of our country . Initial mono resistance to rifampicin is about 2 % of 
patients,  initial mono resistance to  H (isoniazid) is about 18% 4. After the 
overall coverage of the CATEGORY IV regimen in entire country, 
outcome of DR –TB patients found to be improved in the form of high 
cure rate. 
 
            Incidence: 
 Globally  Incidence of  Drug resistance TB  among the new cases 
is about 3.6%, and in previously treated cases about 15.3 % 5 .  China and 
India carry about approximately  50% of the global burden 6 . 
 
 
8 
 
Drug resistance in India: 
 Incidence of the MDR  -TB in new  cases is about 2-3% and in 
retreatment cases about 12 to 17%. In India about 99,000 cases  emerged  
in 2008. As  per  the  Revised  National  Tuberculosis Control  
Programme      (RNTCP )  incidence  of  MDR -TB  due  to Treatment  
defaulters  are  higher in  Uttar Pradesh2  . India  has second highest 
MDR-TB burden in the world after China  . Estimated MDR-TB 
emerging annually are about 99,000 cases, out of which 73,000  (73.7%) 
cases are smear positive 7. Incidence of the XDR TB cases among the re 
treatment  cases is about 4%. 
 
MDR-TB Suspects: 
 New and previously treated patients with treatment failure 
in DOTS  
 Previously treated patient who is sputum smear  positive at 
the end of the fourth month of treatment or later. 
 Contacts of MDR-TB found to be sputum smear positive for 
TB 
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Criteria used for  MDR suspects :  
Criteria A : 
 All failure of  new TB cases 
 Previously  treated  Smear positive cases who remain   
positive  for AFB at 4th   month onwards.  
 Contacts with known MDR-TB cases who become  smear 
positive for AFB 
Criteria B : 
 In addition to criteria A , 
 All cases  of smear positive previously treated cases  
 Follow up smear positive for AFB  among new or 
previously treated cases. 
        Criteria C : 
 In addition to criteria B  
  All smear negative ,  previously treated TB at diagnosis 
found to be smear positive during the follow up  
 HIV positive individual co infected with TB  at the time of 
diagnosis. 
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Definition  for Confirmed MDR-TB case : 
                 Suspected DR-TB patients who are sputum culture positive and  
culture report is  mycobacterium tuberculosis is grown  that are resistant  
to at least isoniazid and rifampicin (the culture and Drug Sensitivity Test  
from an RNTCP accredited laboratory ). Patients with isolated resistance 
to rifampicin are also treated with  CATEGORY IV regimen. 
Methods For Drug Susceptibility Testing (DST) : 
Presently  following three technologies are available for the diagnosis of 
MDR TB 
1. Solid egg – based (Lowenstein- Jensen media)  
2. Liquid culture ( MGIT ) 
3. Rapid molecular assay such as line probe assay (LPA), cartridge based 
nucleic acid amplification test (CBNAAT) 
TIME REQUIRED FOR DST RESULTS : 
Solid LJ media – 84 days 
Liquid culture  ( MGIT ) – 42 days 
LPA – around 72 days 
CBNAAT – results available in 2 hours . 
 
11 
 
           Pre treatment evaluation: 
Drugs used in CATEGORY IV  REGIMEN among MDR-TB  
patients are known to produce many  adverse reactions, and early 
identification and correct management of these adverse reaction will 
improve the adherence of the treatment, so at the time of initiation 
CATEGORY IV  REGIMEN  following assessment is recommended;  
1.Complete  clinical history 
2. Weight measurement 
3. Height measurement 
4. CBC-complete haemogram  and serum eletrolytes 
5.  Diabetes Mellitus screening FBS/PPBS 
6. LFT-liver function test 
7. Serum creatinine and blood urea to assess the current renal 
function 
8. Thyroid function test T3/T4/TSH 
9. Routine complete  Urine Analysis  
10. Pregnancy test (for Child bearing age group females) 
11.Contact screening 
12.Home visit /family planning counselling 
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Pre treatment evaluation will help to identify the high risk groups like  
diabetes, renal disorders,  these baseline investigations are  helpful in 
further follow up visits .  
           Routine Clinical monitoring 
All DR-TB patients are initially examined by medical officer in the 
respective DTO for clinical examination,  and  every month during the 
intensive period,  and once in three months  period during the 
continuation phase till the end of treatment. During the follow up   
medical officer evaluate the patients for clinical improvement and 
possible  drug adverse effects. Patient  may be admitted in the DR-TB 
ward during the treatment period if they develops any adverse drug 
reaction.  Chest X ray to be done routinely at the initiation of the 
treatment and completion of the intensive phase, end of the continuation 
phase treatment. Blood urea and serum creatinine level measurment to be 
done every month during  intensive phase  period, thereafter every three 
months period till end of the treatment.  
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2.A  CATEGORY IV or DOTS PLUS REGIMEN : 
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CATEGORY IV REGIMEN: 
RNTCP is using a  Standardised Treatment Regimen (STR)  for the 
treatment of MDR-TB cases and  rifampicin mono resistance patients are 
also included in treatment of CATEGORT IV regimen . During  Intensive 
phase       (  6-9 months period ) of the Category IV regimen  six drugs are  
used   - Inj. Kanamycin,Ofloxacin (Levofloxacin), Ethionamide, 
Pyrazinamide, Ethambutol  and Cycloserine . In the continuation phase 
four drugs are used, namely  Ofloxacin (Levofloxacin), Ethionamide, 
Ethambutol and Cycloserine for  next eighteen months period. P -
aminosalicylic acid (PAS) is included in the regimen as a substitute drug 
if any other above mentioned drugs  are contraindicated . 
Drug Administration ;  
All drugs are to be given in a single daily dosage under supervision 
by a DOT provider. These  drugs to be given to the patients under direct 
observation for six days of the week. On the 7th day (Sunday) the oral 
drugs will be administered unsupervised, whereas injection kanamycin 
will be omitted. During the treatment if any intolerance occurs to the 
drugs, Ethionamide , Cycloserine  and PAS may be divided  into two 
dosages and the morning dose is  administered under supervision 8. The 
evening dose will be self-administered.  Pyridoxine  is given routinely for 
all patients treated with CATEGORY  IV regimen . 
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Dosage and weights band recommendations : 
 
NO 
 
DRUG  
 
16-25 Kg 25-45 Kg >45 Kg 
 
1 
 
Kanamycin  
 
500mg 
 
500mg 
 
750mg 
 
2 
 
Ofloxacin 
(levofloxacin) 
 
400mg 
(200mg) 
 
600mg 
(500mg) 
 
800mg 
(750mg) 
 
3 
 
Ethionamide  
 
375mg 
 
500mg 
 
750mg 
 
4 
 
Ethambutol 
 
400mg 
 
800mg 
 
1000mg 
 
5 
 
Pyrizanamide 
 
500mg 
 
1250mg 
 
1500mg 
 
6 
 
Cycloserine 
 
250mg 
 
500mg 
 
750mg 
 
7 
 
PAS 
 
5gm 
 
10gm 
 
12gm 
 
8 
 
Pyridoxine 
 
50mg 
 
100mg 
 
100mg 
 
Monitoring of Adverse Reactions 
Close monitoring  for the  patients receiving the CATEGORY IV  
regimen is a very important step, so early detection and proper  treatment  
16 
 
of adverse effects caused by the above mentioned drugs is essential  for 
good compliance  of the patients and prevent the permanent hearing loss.   
Common adverse reactions : 
1.Inj- Kanamycin 
 Hearing impairment 
 Renal failure 
 Vertigo 
 Electrolyte disturbances 
2 Quinolones  - Llevofloxacin/ Ofloxacin 
 Nausea , vomiting, epigastric pain 
 Convulsions 
 Phototoxicity / photosensitivity 
 Tendinopathy / tendinitis 
 Renal Insufficiency 
 Skin Rash 
 Cardiac Arrythmias 
 Joint Pain and joint swelling 
3 Ethambutol 
 defective vision , colour blindness  
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4 Pyrazinamide 
 Joint pain 
 Increased uric acid level, hepatic injury 
 Itching  
5 . Ethionamide  
 Epigastric pain, loss of appetite , nausea, altered  taste 
sensation, vomiting,  salivation, 
 Psychiatric : hallucination rarely depression 
 Injury to liver and  altered thyroid function noted on 
long term use. 
     6.PAS 
 Severe gastriris 
 Persistent Nausea and vomiting 
 Liver damage 
 Hypokalemia 
 Thyroid dysfunction 
 hyper sensitivity 
 skin rash 
 7.  cycloserine 9   
 sleep disturbances, convulsion, altered behaviour 
 suicidal tendency, 
  depression 
18 
 
 
 
 
 
 
 
 
 
 
 
2.B.KANAMYCIN – DRUG PROFILE 
 
 
 
 
 
19 
 
KANAMYCIN 
Kanamycin is isolated from streptomyces kanamyceticus (1957), it 
was the second  systemically used aminoglycosidal antibiotic developed  
after streptomycin. Kanamycin produces ototoxicity and nepdrotoxicity , 
more cochlear toxicity than vestibular toxicity. 
 
Mechanism of action: 
Kanamycin is a bactericidal antibiotic. It exhibit the cidal 
action in two steps 
a) transport of the aminoglycoside into the bacterial 
cell wall and cytoplasmic membrane 
b)  inhibits the protein synthesis  by binding the 50 S 
ribosomal unit  
T ½ : 2 to 4 hours 10 
Cidal action of aminoglycoside is concentration dependent i.e. rate 
of bacterial killing is directly proportional to peak antibiotic 
concentration. Because of this post antibiotic effect, despite of 
short  t ½ once daily dosage of injection kanamycin is more 
effective when compare to divided doses.    
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 Dose : 
    Adults- 15 to 20 mg /kg  daily,  maximum of 1000 mg 
Adult with creatinine clearance < 30 ml/min – 12 to 15 mg /kg two 
to three times in a  week 
    Safe in patients with hepatic disorder 
 
Contraindication :  
          Pregnancy ,  
          myasthenia gravis 
          severe renal failure   
           hearing impairment 
KANAMYCIN – SIDE EFFECTS : 
1. Ototoxicity: 
Aminoglycoside induced ototoxicity is dose and duration dependent 
manner,  vestibular apparatus or cochlea or both can be affected by 
kanamycin.  The drug is concentrated in the labyrinthine fluid and  slowly 
removed from the fluid when plasma concentration falls. 
Hair cells present in the inner ear undergo concentration dependent  
destructive changes, initially it affects outer hair cell, later it affects inner 
hair cell, so kanamycin induced ototoxicity initially involves higher 
frequencies, then lower and speech frequencies 11. 
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Cochlear damage: 
          Aminogycoside induced damage first involves the base of  
cochlea and spreads to the apex of  cochlea, so kanamycin induced 
hearing loss is progressive in nature.  Free  radicals produced by   
Kanamycin in  the labyrinthine fluid , damages hair cells    in the cochlea, 
once sensory  hair cells are  damaged due to any insult no regeneration of  
hair cells occur, hence kanamycin induced ototoxicity is permanent . 
       Initial ototoxicity is asymptomatic, may be detected by 
audiometry, then tinnitus appears one week later, at that time hearing loss 
developed to the particular frequencies  persists  life long. 
 
 
Vestibular damage : 
  Acute phase -  Headache is the first most commonly observed 
symptom then develops nausea, vomiting, nystagmus, ataxia   
 Chronic phase -  it starts  six to ten weeks after starting the 
aminoglycosides. It affects the balance mechanism and  in this stage 
patient will have  difficulty in walking.   If the drug has been stopped in 
the acute stage  patient may not enter into the chronic stage   . 
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2) NEPHROTOXICITY: 
Kanamycin induced renal toxicity is reversible, these drugs are 
highly concentrated in the  renal cotex, toxicity is directly related to the 
dose of the drug patient received.  
Elderly patients  and diabetics are more prone to develop 
nephrotoxicity. In renal failure patients, high blood levels of kanamycin 
will produce ototoxicity. 
3. Neuromuscular dysfunction 
4. Electrolyte imbalance 
5. Injection of kanamycin gives local side effects like pain, 
swelling , abscess     
. 
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2.C.ADVERSE DRUG REACTION AND 
MANAGEMENT IN MDR-TB PATIENTS 
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MDR TB AND RENAL TOXICITY:  
Prior to initiating   CATEGORY IV regimen ,  renal function  is to 
be evaluated in all patients. If the patients noticed symptoms or signs of 
renal insufficiency like reduced urine output (oliguria) ,absence of urine 
output ( anuria), facial puffiness , pedal edema , all the drugs should be 
withheld,  nephrologist opinion should be obtained 12. Re-introduction of 
drugs will be decided by the DOTS-Plus site committee , along with 
frequent monitoring of renal function test . Common offending drug in  
MDR-TB patients on   CATEGORY IV regimen is  an aminoglycoside. 
Renal function monitoring to be done every month for the first six 
months period of the CATEGORY 4 regimen and then every three 
months  till the end of  treatment  . In asymptomatic patients renal toxicity 
may be picked  up by these  routine follow-up  renal function test.  
Renal insufficiency may be due to longstanding TB disease itself, 
previous use of aminoglycosides or concurrent renal disease . Great care 
should be taken in the administration of second-line anti TB drugs in 
patients with renal impairment 13. Dose reduction is required for second 
line drugs such as ethambutol, quinolones, cycloserine and PAS in case of  
mild  to moderate renal insuffciency . In  case of severe renal failure most 
of the drugs in CAT IV regimen needs dose  adjustments according to the 
25 
 
creatinine clearance. Potent non nephrotoxic drug may be substituted in 
case of severe renal failure  
 
Management of  nephrotoxicity : 
Offending drugs; Streptomycin / Kanamycin / Amikacin / 
cycloserine   
1. Stop the suspected drug in the regimen. 
2. Alter the  suspected drug dose  3 times per week and 
monitor creatinine clearance. 
3. Adjust dose of all the drugs according to creatinine 
clearance. 
4. Consider use of capreomycin if patient was on 
aminoglycoside. 
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Recommended Dose and Interval adjustment in renal 
disorder:  
Dose adjustment and interval adjustment of kanamycin is 
needed in patients with renal insufficiency  according to glomerular 
filtration rate – ml/mt. 
 Less than 10 – 3mg/kg/48hrs 
 10 to 50 – 4 to 7.5 mg/kg/24 hrs 
 More than 50 -7.5 to 15 mg/kg/24 hrs 
DR-TB may also be associated with other serious disorders, 
such as HIV infection, alcoholism, renal failure, diabetes mellitus, 
cancers and drug abuse. The signs and symptoms of these 
conditions and their complications can easily obscure those of DR-
TB and can also result in considerable delays in diagnosis or in 
misdiagnosis, especially in patients with HIV infection 14. 
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MDR-TB and Ototoxicity 
Defective  hearing  is mostly due to the aminoglycosides used in 
CATEGORY IV regimen  which is dose dependent . Hence  periodical  
monitoring of ototoxicity  by using  pure tone audiometry is 
recommended. If patient develops tinnitus,vertigo audiometry to be done 
during the first six to nine months in the intensive period  .   Patients with 
history of hearing impairment  should be counselled for the high risk of 
developing  ototoxicity and counselling with written consent should be  
obtained before these aminoglycosides are used. 
 Drugs may causing Hearing loss in MDR/XDR Patients : 
Km- Kanamycin 
Am- Amikacin 
Cm- Capreomycin 
1. Conduct PTA  and compare with baseline audiometry. 
2. Consider reducing the  drug administration to five times 
or even three times per week. 
3. Reduce  the dose of suspected drug if this will not 
compromise the regimen. 
4. withheld the offending  drug if this will not compromise 
the regimen. 
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If  hearing loss is detected during the treatment, options 
available   are to stop the drug, reduce the dose, increase the 
dose interval or retain current therapy and also suggest the 
alternative  non ototoxic drugs.  
 
 
Management of Adverse Drug Reactions 
Importance to be given to treat the patients with CATEGORY IV 
regimen and also proper management of adverse reactions12 . Drugs used 
in the CATEGORY IV regimen   had more adverse  drug  reaction than 
drugs used in new and previously treated TB patients13. 
 
Early identification and correct treatment to be given if these 
Adverse drug reaction starts with pre-treatment  evaluation  
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DIABETES: 
Poor outcome of the MDR TB patients  may be due to  poor 
glycemic control and  diabetes may augment these adverse drug reactions,  
long term uncontrolled diabetes itself may cause renal impairement , 
peripheral neuropathy and diabetic retinopathy 
Oral hypoglycemic drugs can be safely given with second-line 
drugs, but ethionamide and prothionamide may affect the glucose 
metabolism this will reflect on management of diabetes . 
 
MDR TB with Diabetes  the following is recommended: 
 Diabetes properly treated during the course of the CATEGORY 
IV  regimen. 
 Patient education:     about the dietary management , walking, 
foot care, treatment compliance.  
Counselling  for  the symptoms of hyper and hypoglycaemia and 
how to manage them properly . 
 Glucose monitoring 
1.)  Aim  for fasting capillary blood sugar level is about  80-
120 mg/dl  in morning,  100-140 mg/dl before bedtime.  If 
patient experienced hypoglycaemia sugar values  may be 
maintained in higher values.  
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2.)  Advice to do a periodic glucose monitoring until patient 
had a stable glycemic status. If patient achieved stable 
glucose level, glucose monitoring done at monthly interval. 
 Regular monitoring 
1.) serum electrolyte monitoring done for every month for the 
first  six months in the intensive period and then every three 
monthly period till end of the treatment. 
2.)  If the serum creatinine level rises, creatinine clearance 
should be checked and the second-line anti-TB drugs should be 
adjusted accordingly. Once the dose is adjusted, the serum 
creatinine should be checked weekly until it has stabilised. 
3.) HbA1C to be done for every three months period if  patient 
had poor glycemic control . In patients with good  glycemic 
control HbA1C to be done for every six months period. Target  
HbA1C <7. 
4.) ophthalmological examination is to be done annually. 
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 Screening and treatment for hypertension   
  1.) Measurement of blood pressure for every month 
as a routine measurement 
2.) Hypertensive patients with diabetes treated with ACE-
inhibitor. 
 
 Prevention of diabetic nephropathy 
1.) Dose adjustment to be done in the  second line injectable 
anti TB drugs  based on the creatinine clearance. 
2.) Consider using an ACE inhibitor in patients with 24 hours 
urine albumin level >300 mg. 
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2.D.The Physiology of Hearing and Balance 
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The Physiology of Hearing and Balance 
  Auditory sounds are  conducted from pinna to tympanic membrane 
via external auditory canal, from here these vibrations transmitted to the 
middle ear by auditory ossicles ( the malleus, incus and stapes) . Handle 
of the malleus is attached to the back of  tympanic membrane. Foot plate 
of the stapes is attached to the oval window,  and then vibration entering 
the cochlea  reach  the hair cells  which is situated in the Organ of Corti.  
spiral ganglion located in the base of the hair cell.  
 
Fig.1: 
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              Afferent signals from vestibulocochlear nerve  ends in the dorsal 
and ventral    cochlear nuclei, from here auditory impulse reaches inferior 
colliculi , then medial geniculate body which is  situated in the thalamus 
,then signals ends in the primary auditory cortex (Brodmann area 41). 
In  the auditory canal most commonly  blocked by  wax, discharge 
from the middle ear can interfere process of hearing  . Perforations of the 
tympanic membrane , middle ear effusion, and  ASOM, CSOM 
(Suppurative otitis media) leads to condutive type of hearing loss. 
  Acute and chronic supurative otitis media , multiple perforation in 
the  tympanic membrane  are more  common in HIV‐infected patients, so 
careful pre treatment auditory evalution is mandatory for HIV patients 
with DR-TB . 
 
Physiological Mechanism of Balance : 
 Balance is a complex process involves  rotational acceleration and 
linear acceleration, this process involves the scala vestibuli  situated in  
the cochlea.  Movement of  labyrinthine fluid  through the three 
semi‐circular canals, and  into  the maculae, utricle and saccule , 
stimulates hair cells which in turn create signals in the vestibular nerve. 
This vestibular nerve runs  along with the cochlear nerve it is called as the 
vestibulocochlear neave . Eighth cranial nerve nuclei is situated in the 
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brainstem ( medulla) , from medulla afferent signal is transmitted to the 
auditory cortex . 
  Vestibular nuclei are primarily  related to the position of the head , 
signals descend from these nuclei control  head on neck and head on body 
movements, ascending signals from these nuclei concerned with extra 
ocular movements. 
 
Fig.2: 
The aminoglycoside  drugs selectively destroy the  hair cells which 
is present in the basilar membrane, these  outer basal hair cell is important  
for high frequency hearing, inner hair cell responds for low frequency 
hearing 15  
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Aminoglycoside induced hearing loss  usually starts with high frequency 
loss , because these drugs are concentrated in the labyrinthine fluid which  
selectively destroys the  outer hair cell. If aminoglycoside used for longer 
duration it also affects the lower frequency then lastly  affects speech 
frequencies by destroying  the inner hair cell.  Destroyed hair cell does not 
have  the capacity to regenerate16.  These damage produced by 
aminoglycosides  is usually irreversible. Aminoglycoside also  affects the  
vestibular function  leading to impaired balance mechanism.  
 
Importance of The  hearing test  in MDR-TB patients : 
In India audiological  examination is  usually done in patients with 
hearing problem. If hearing test is widely available , it  may be done as a 
screening test for all  MDR TB patients who are going to start 
CATEGORY IV regimen.  PTA is  available in  tertiary  care hospitals 
and  usually    done in patients  who complaints  of  problems with 
communication,by that time hearing loss may involve speech frequencies 
which is usually irreversible. 
If  PTA is carried out  in a regular interval in MDR –TB patient 
and high frequency  sensory neural hearing loss is detected in earlier stage 
of the treatment course, it is possible  to alter the drug regimen with non 
ototoxic  drugs  before hearing loss involves  speech frequencies. It is also 
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useful to suggest the hearing aid for improve the hearing. Success of the 
treatment outcome in an MDR-TB patients also depends on management 
of this adverse drug reaction as mentioned earlier. 
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2.E.TESTS FOR HEARING 
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Test for hearing : 
 Clinical Examination  
otoscopy - visual inspection of  the  external auditory canal 
and tympanic membrane by  using  an otoscope 
auditory canal- look for  furunculosis , foreign body , wax or 
mass 
 Otoscopic Examination of  the tympanic membrane-  look  
for any  perforation , fluid collections and infections. 
 
 Tympanometry 
    Tympanometry  is used to assess the middle ear function.  
Probe used for tympanometry  is placed in the patients external ear 
canal and the movement and  mobility  of the tympanic membrane 
is  assessed .  
 
 Audiometry 
For adults and older children with normal mental status 
the current  method  for the test of hearing is  pure tone 
audiometry. This test is done  in a sound‐proof room , 
headphones placed over the patient’s ears. The patient is asked 
to raise a hand  when they hear a sound.  
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Sound frequency tested for audiometry are in the range of 
125Hz  to 8,000Hz17. For both ears sound frequency was tested 
seperately by using masking method. Audiometry report was 
given in the prescribed format as given in figure 1. 
 
Fig  3. Pure Tone  Adiometry 
 
PTA should be done in co-operative patients  with normal mental 
status. PTA  can be done in  normal children age above five years  by 
using play techniques. In an expert hands children less than five year can 
be encouraged to participate and  usually it is very difficult to get a 
cooperation for  audiometry. In such cases oto acoustic emission test is 
useful. 
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OAE - Oto Acoustic Emissions: 
OAE is a spontaneous sound produced by a normally functioning 
cochlea, these sounds produced by a motion of the cochlear sensory hair 
cell,  which is measurable with sensitive microprobes in the external 
auditory canal. It is a simple , non invasive test used in new born babies, 
younger children and 
patients  not able to co‐operate for audiomerty. These sounds  are 
produced spontaneously but can also be stimulated (figure2). 
 
Fig 4. Oto Acoustic Emissions 
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These tests can determine the patency of the auditory circuit within 
the cochlea but do not establish if the patient can actually hear or not. 
Functions of the outer and inner hair cells is assessed by using  the OAE. 
 Injection kanamycin induced ototoxicity is due to damage 
occurring in the hair cells,so detection of hearing loss by using  oto 
acoustic emissions is likely to be satisfactory. 
 
Advantages for this procedure 
 Results  will be available immediately 
 OAE can be done in chronically ill / bed ridden patients 
 Patient concentration not required 
ABER- Auditory Brainstem Evoked Response :  
It is an objective way of demonstrating the brain stem potential in 
response to audiological click sound, Used  to measures the entire 
sensorineural pathway of hearing,  these waves are recorded by electrodes  
placed over the scalp. Multiple electrodes are placed in the scalp at 
various points, BERA probe is placed in the auditory canal. Click sound is 
given to the Auditory canal and the signal in waveform is received from 
the scalp electrodes.These waveforms are analysed by an audiologist. 
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Fig 5. Auditory Brainstem Evoked Response 
 
ABER can be done in  newborn period, intensive care unit patients, 
patient with demyelinating disorder. 
Disadvantages: 
   For this procedure younger children needs sedation.  
           ABER  is available in limited centre 
     Categorising hearing loss 
1) Hearing loss may be conductive or sensorineural or both 
2) Unilateral or bilateral 
3) Mild , moderate , severe, profound  
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           WHO CLASSIFICATION OF HEARING LOSS 18 : 
 
Classification Decibels (dB) 
Normal < 25 
Mild 26 to 40 
Moderate 41 to 55 
Moderately severe 56 to 70 
Severe 71 o 90 
Profound >90 
 
     Definition for ototoxicity  (American Speech and Hearing Association) is  
any of:  
a.)  20dB decrease at any one frequency, 
  b.) 10dB decrease at any two adjacent frequencies or  
c.) loss of response at three consecutive test frequencies where 
responses were previously obtained. 
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How to read  Audiometry reports ?  
In the Audiogram graph,  frequency (Hz) is measured in the 
horizontal axis from low (125Hz)  to high(8000Hz) range. Intensity of the 
sound is measured  in decibels, range between -10 dB to 120 dB (soft to 
loud) in the vertical axis.  
   
 
Fig 6. Audiogram graph 
1)  In the audiogram graph patient cannot hear  area above the line. 
2) Air conduction and bone conduction measured seperately 
3) Air bone gap   <10 db present  in normal persons, SNHL 
4) Air bone gap more than 10 db means conductive hearing loss  
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Common terminology criteria for adverse events  (CTACE) was classified the 
drug induced hearing loss into 4 grades 19  as follows: 
Grade 1 –threshold shift of 15 to 25db averaged at least two contiguous test 
frequencies in at least one year 
Grade 2  -  threshold shift of more than 25db  averaged at least two contiguous 
test frequencies in at least one year 
Grade 3- threshold shift of more than  25 db averaged at  three contiguous test 
frequencies in at least one year 
Grade 4 – threshold of more than 80 db at 2000Hz and above, corresponds to 
profound bilateral hearing loss.  
Following  figure 5 shows categorisation of hearing loss in the audiogram graph. 
Top of the graph shows normal audiometry pattern. Normal person hear the 
sounds less than 25db in all frequencies.  
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Fig 7. Classification  of  Hearing  Loss 
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Figure 8 shows normal pattern of hearing , both ears shows 25 db hearing 
loss at 4000 Hz. Reported as normal   
 
Fig 8. Normal 
Figure 9 shows  bilateral moderate hearing loss , started from 2000 Hz 
 
 
Fig 9. Moderate Hearing Loss Range Beginning at 2000 Hz 
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Figure 10 Normal pattern of hearing on left ear, right sided severe hearing 
loss according to WHO classification 
 
Fig 10. Left – Normal , Right Severe Hearing Loss 
 
 
 
 Figure 11 shows bilateral profound hearing loss involving the speech 
frequencies 
 
Fig 11. Bilateral Profound Hearing Loss 
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REVIEW OF LITERATURE 
Ashishkumar C Zala  et al 20  in  department  of  pharmacology ,   
government medical  college ,  surat , conducted  the  study  assessment  
of  prevalence  of  kanamycin  induced  ototoxicity  in  MDR  TB  patients 
. In  this  prospective  observational  study  100 MDR TB  cases  were  
enrolled .   Clinical and audiological  examination was done in  all  
patients  at  the  initiation  of  DOTS PLUS  regimen ,  and  monthly  for  
six  months  period  in  the  intensive  phase  of   the  treatment. In this  
Study  was  conducted  from  January  2013  to  may   2014 . 
 All  newly  diagnosed  MDR TB  patients  was   included in this  
study, at the time of initiation of drug  treatment  evidence  of   hearing  
loss  and  congenital  deafness  and infective  pathology involving   the  
ear  like  CSOM ,  meningitis  , any  surgical  procedure  in  the  ears ,   
concomittent  use of  any  ototoxic  drugs  are excluded. In  this  study  35 
%  patients  develops  mild  to  moderate  bilateral  sensory neuronal 
hearing loss  ,  65%  patients  without  hearing loss  during  the six  
months  period.  During  the   Intensive  phase   of  the CATEGORY IV  
REGIMEN  35%   patients develops   SNHL  ,  among  these   62.85 %  
(n=22)   patients  develops  SNHL during  the  first  month  period ,  11.4 
%       ( n=4)  during  2nd  month  of  treatment  ,  2.85 %   (n=1)   
developing  SNHL  3rd  month  follow  up  period, 8.57 %   (n=3)  during  
4th  month  ,    8.57  %   (n=3 ) on  5th  month  ,  5.71 %(n=2)  developed  
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SNHL  on  6th  month  follow up period .   In  this  study population  
diabetes  and  HIV  status  not  mentioned.  
Prahlad  Duggal 21  et  al   in  the  year   2007 ,  conducted  the  
study  of  audiologic  monitoring  of  MDR TB  patients getting  
aminiglycoside  treatment  with  follow up was done a  longer period.  In  
this  study   64  newly  diagnosed   MDR TB patients   were  included  .  
They   are divided in to three  groups,  
Group 1 -   Thirty four  patients   administererd  inj .  Amikacin  
(dose is 15  mg  /  kg   /  day as a singleIM   dose)  ,  Group 2 -   twenty 
six   patients  are received    inj  . kanamycin (dose is  15  mg /  kg  /  day 
as a   single IM  daily dose ) ,   and   group  3  -  four  patients  are  using  
inj .  capreomycin ( dose was 15  mg  /  kg  /  day as a single IM  dose). 
These  drugs  given for   the  period  of   six  months .  All  patients  in  
the  study  groups  followed  up for    one  year during the treatment,  also  
after  discontinuation of aminoglycoside   for  the  next  one  year  period  
. among them  18.75  %     patients   developed  SNHL  involving  higher  
frequencies  , and    also  6.25  %  patients  hearing loss  involved    
speech  frequencies  .  after  one  year  of  discontinuation   of  
aminoglycosides  all  patients  were  re-examined   and   found  that  all  
hearing  loss  are  permanent   also  no  threshold  improvement  .  In  
Group  2  - four patients 15.4  %  ( n = 26 )  had  hearing loss   involving   
higher  frequencies .   Two  patients  7.7 %  ( n = 26 )  had  low frequency  
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hearing   loss  . total   duration  of  the  aminoglycoside  use  in  this  
group 2   was   237 days  +_  34 days . In  this  study    audiometry  ( 
PTA)  was  performed  every  month  until  the  Completition of  the    
treatment.  Renal toxicity , diabetic status  and  ,  HIV status  are  not  
mentioned  in  the  study   . 
Ann  sturdy  et  al 22  conducted  a  retrospective  study  of  DR  TB  
treatment  in  the  United Kingdom  ;  a  study  about   aminoglycoside  
use  and  toxicity  in DR-TB patients  .This  study  was conducted  in  five  
DR  -  TB  centres  in  UK  between  Jan  2004  and  Dec  2009 ,  study 
about the  incidence  of  ototoxicity   for  both  clinically  and audiometry  
testing and  also  factors  contributed  with hearing impairement were 
analysed.       Outcome   :  1 )  Total   fifty   DR-TB   patients , 29  patients   
( 58 % )  received Inj. amikacin   ,  11  out of  50 patients   ( 22% )  
received  inj. capreomycin  and   10  out of  50 patients (  20 % )  were 
administered inj.  streptomycin  or  combination  . 21 /50 patients  ( 42 % 
)  patients  receiving  basic audiological evaluation within  two weeks of 
initiating  treatment ,  and  16  out of  50  ( 32 % )  had  monthly  
audiograms  ,  12 /  50  ( 24 %)  not receiving  any  audiological  
screening  during  the  treatment .   2.) among the  50  patients  ,  14 
patients  ( 28 % )  developed  ototoxicity  with  9  out of fifty patients   ( 
18 % ) had permanant  hearing impairement .  Use  of  amikacin ,  
increasing  age  decreased renal function  were  significantly  associated  
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with  ototoxicity  .Nephrotoxicity  was  defined  in  this  study  was  
increasing  creatinine  values  from  baseline  of  more  than  44  
micomoles / litre  at  any  time  during  treatment  .  In  this  study  7 (14% 
)  patients  developed  nehrotoxicity  during the  treatment  ,    38   (  76  
%  )  normal  creatinine  values  . among the fifty patients  5 (10%)  
patients HIV   positive  ,   45  ( 90 % )  HIV - non  reactive   
Mohammad  Reza  Javadi  et  al  conducted  the  study  in  the  year  
2007  ,The   Incidence  of  Amikacin   induced   Ototoxicity  in  DR-TB   
Patients   was higher  in  men  than  in  women . The  hearing  threshold  
values  was significantly  increased  after  the  amikacin  treatment  in   
MDR-TB  patients  . incidence of the hearing impairment was  significant  
in  MDR –TB  patients treated  with  inj.amikacin.  In  this  study  41  
patients  received  a  fixed  dose  of  IV  amikacin  ( 500  mg  daily  as  30  
min  IV  infusion  over  30  min  )  combined  with   the second  -  and    
third – line  drugs  for  MDR – TB  for   six  months  period patient with 
pre treatment hearing problem like  congenital deafness   and  congenital  
abnormalities  and  also  patients with evidence  of  infective  process 
involving   the  ear , previous history of meningitis  , chronic otitis  media 
) , surgical procedures  and  the  ones  using  simultaneous use of 
ototoxic  drugs  were used as  exclusion criteria for the  study . Basic 
audiological evaluation    Pure –Tone  Audiometry  (PTA)  was done pre 
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and the post terament period . Total  of  29  patients  suffered  from  
hearing  impairement ( 70 . % )   ( Male :n = 18;  Female : n  = 20 ). 
Hearing  impairment  was bilateral  in  18 patients  ( 62.06 % )  and  
unilateral  in  11  patients  ( n  =  6  right  ear  and n =  5    left  ear ) .          
 
The  severity  of  ototoxicity   was    varied  widely  from patient  to  
patient  ( mild  ototoxicity :  about  44.83 % ;  moderate ototoxicity :  17 . 
24 % ;  moderately  severe  ototoxicity : 24 . 14 % ;  severe  ototoxicity : 
10 . 34 % ;   profound  ototoxicity :  3.45%  ) . In  this  study , age ,  
cigarette  smoking  or  drug  abuse ,  do  not  significantly associate with  
the  incidence  and  progress  of  cochleotoxicity  
 
Tashneem harris 23 et al conducted a  prospective cohart  study about   
aminoglycoside induced hearing loss in HIV positive and negative pateint 
with MDR TB, result is 70% HIV positive patients developed hearing loss 
compared to HIV negative patients. HIV positive patients are at increased 
risk for developing hearing loss . In this study some patients developed 
severe hearing loss  following single dose of kanamycin. This  shows 
genetic susceptibility also plays important role for developing hearing 
loss.  
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In this study six MDR-TB patients had mitochondrial mutation involved 
in  MT-RNR 1gene. This mutation involved aminoglycoside releated 
toxicity. In this study 70 %  HIV   positive patients developed hearing 
loss, no association found between degree of hearing loss with HIV status. 
 
Elida mustikaningtyas 24 et al conducted a prospective observational study 
in Indonesia, to assessing the prevalence of hearing loss in MDR-TB 
patients in the year 2011. Study results was 36.6% of the patients are in 
between 31 to 40 years of age.  53.7 % patients developed asymptomatic 
hearing loss, 46.3% developed symptomatic hearing loss. Pure tone 
audiometry result showed 48% patients showed mild hearing loss, 24 % 
patients had moderate hearing loss.by using oto acustic emmison 54.87% 
had cochlear disease , 28.04% had normally functioning cochlea.            
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4. MATERIALS AND METHODS 
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Material and methods  
Aim : 
  Audiologic monitoring and renal function monitoring for Drug 
Resistant patients under PMDT( programmatic management of drug 
resistant tuberculosis reatment ) for six to nine months period in 
Tirunelveli Medical College Hospital DR-TB UNIT, from January  2014 
to December 2014.   
MATERIALS AND METHODS : 
   Total of 152 newly diagnosed DR-TB patients those registered in 
DR-TB centre , Tirunelveli medical college hospital   from January 2014 
to December 2014 were screened.  
 INCLUSION CRITERIA 
 All newly diagnosed DR-TB patients in tirunelveli, tuticorin, 
kanyakumari, virudhunagar districts in Tamilnadu state with normal 
baseline audiometry    and normal serum urea and creatinine levels were 
included in this study    
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EXCLUSION CRITERIA  
1. Pre treatment evidence of hearing loss in newly diagnosed DR-
TB patient with baseline audiometry  changes more than 25 db 
2. Patient with prior history of  audiological impairment, 
presbyacusis, any vestibulo-cochlear symptoms  
3. Patients with age less than 10 year 
4. Pregnant females 
5. Patients not willing for routine follow up  
6. Patients with elevated renal parameter at the time of initiation of 
the DOTS PLUS regimen. 
7. Major psychiatric illness 
Methods : 
  After getting the permission from the institutional ethical 
committee in  Tirunelveli Medical College Hospital study commences,  
this prospective observational study  was conducted  from DR-TB unit in 
tirunelveli medical college . Informed  Consent will be obtained from DR-
TB patients admitted in DR-TB ward. This study starts  after explaining 
the treatment regimen and probable adverse effects expected in the course 
of the treatment .  
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  All newly diagnosed DR-TB patients admitted in  DR-TB unit for 
DOTS PLUS regimen initiation  in Tirunelveli Medical College were  
included in study group. 
  After  using inclusion and exclusion criteria  51 eligible newly 
dignosed  DR-TB patients were enrolled in this study .These patients were  
started on  CATEGORY IV regimen according to weight basis. Pure tone 
audiometry was done in  the ENT department in tirunelveli medical  
college.  
 
AUDIOMETRY: 
1. First Pure tone audiometry was done at the time of initiation 
of the CATEGORY IV regimen. 
2. Second pure tone audiometry was done at third month of the 
treatment. 
3. Third   pure tone audiometry was done at sixth month of the 
treatment. 
4. If patients develops tinnitus, vertigo, hard of  hearing or any 
audiological impairement ,  pure tone audiometry was done 
in the intensive phase.  
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RENAL FUNCTION TEST : 
1. Blood urea and serum creatinine was done at the time of initiation 
of treatment. 
2. Follow up renal function test done at 3rd and 6th month period of 
the treatment. 
3. If patient noticed facial puffiness, pedal edema, reduced urine 
output during the intensive period renal function test done at any 
time in between the treatment. 
 
At the initiation of the CATEGORY 4 regimen for all DR-TB  patients  
following investigation is required 
 HEMOGLOBIN level, 
 HIV status, 
 DIABETIC screening for all patients 
DURATION OF THE STUDY : 12 months( January 2014 to december 
2014) 
SAMPLE SIZE :  51 
STUDY DESIGN : prospective observational study 
SOURCE : MDR-TB Patients registered in DR-TB unit , Tiruneveli 
medical college hospital 
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WHO CRITERIA FOR CATEGORISING  HEARING  LOSS : 
 Normal – amplitude less than 25 decibels 
 Mild – amplitude 26 to 40 decibels 
 Moderate- amplitude 41 to 55 decibels 
 Moderately severe- amplitude 56 to70 decibels 
 Severe - amplitude 71 to 90 decibels 
 Profound -  amplitude more than 90  decibels 
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5.RESULTS 
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 ANALYSIS : 
 Total of  51 newly diagnosed DR-TB patients were included in this 
study.  Pure tone audiometry and renal function monitoring  was done and 
analysed as follows 
 
AGE DIRSTRIBUTION : 
 
 Out  of  51 patients , 27 % (n -14) of the patients belongs to 
the age group of  41 to 50 
 24% of the patients (n-12)belongs to the  the age group of 
31 to 40 years 
 18% of the patients (n-9) belongs to the age group of  
21to30 years 
 18% of the patients (n-9) belongs to the age group of  51to 
60 years .  
 8% of the patients (n-6) belongs to the age group of  61 to70 
years  
 6%of the patients (n-4) belongs to the age group of  11 to 20 
years.  
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Fig 12. Age Distribution 
Age Number Percentage 
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SEX DIRSTRIBUTION: 
Out  of 51 MDR-TB patients,82% ( n- 42) patients are males,18% 
(n-5)  are females 
 
                     FIGURE 13; SEX DISTRIBUTION 
 
Out of 51 MDR-TB patients   22 patients  developed SNHL, 
among which  81% (n-18) are males  ,18% (n-4) are females . 
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  DIABETES MELLITUS 
 Among the 51 patients 20%(n-10) patients are 
diabetic 80% (n-41) are non-diabetic.  
 70% of diabetic patients  developed SNHL, Among 
these  86% (n-6) are males, 14% (n-1) are females. 
 
                      
 
Fig 14. Diabetes in MDR TB 
       
 
Diabetic
20%
Non-Diabetic
80%
68 
 
 
 HIV SATUS : 
 In 51 DR-TB patients, 5 patients are HIV  positive,  
3 patients are males, 2 patients are females.  
 One male patient developed right sided severe 
hearing loss during follow up period. 
 
Fig 15. HIV in MDR TB 
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 DEGREE OF HEARING LOSS 
 UNILATERAL HEARING LOSS :  TOTAL-8 
 Total of 51  DR-TB patients,  8 patients (n-8) developed 
unilateral hearing loss. 
 Among them 7 patients had mild hearing loss ( male-6, female -
1), one  had moderate hearing loss . 
 
DEGREE RIGHT LEFT 
MILD 4  ( M 4 / F 0) 3   (M 2 / F 1 ) 
MODERATE 1  (M 1 / F 0) 0 
MODERATLY SEVERE 0 0 
SEVERE 0 0 
PROFOUND 0 0 
Table 2 : Unilateral Hearing Loss 
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BILATERAL HEARING LOSS : TOTAL 14  (M 11 / F  3 ) 
 Out  of 51 patients  , 14 patients (28ears)  developed bilateral 
hearing loss, among these patients 11 were males, 3 were 
females, 
 In this group 9 patients developed bilateral mild SNHL , 1 
patient had  severe hearing  loss , one patient had right sided 
profound hearing loss and  left severe hearing loss on  3rd 
month of follow up 
 
DEGREE RIGHT LEFT 
MILD 1 - 
MODERTE 1 1 
MODERATLY 
SEVERE 
1 3 
SEVERE 1 1 
PROFOUND 
1 0 
Table 3 : BILATERAL SNHL 
NUMBER OF  PATIENTS DEVELOPED B/L MILD SNHL: 9 
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PERCENTAGE OF HEARING LOSS FOR USING WHO 
CLASSIFICATION  : 
Out  of 22 patients who developed SNHL (44 ears) ,  75%  (33 ears )  
patients   developed mild hearing loss, 9.1% (4 ears ) patients developed 
moderate hearing loss, 9.1%(4 ears ) patients  developed moderately 
severe hearing loss, 4.5 % ( 2 ears ) developed severe hearing loss, 2.3% ( 
1ear ) developed profound hearing loss. 
 
 CATEGORY NO OF EARS PERCENTAGE 
MILD 
33 75% 
MODERATE 
4 9.1% 
MODERATELY 
SEVERE 
4 9.1% 
SEVERE 
2 4.5% 
PROFOUND 
1 2.3% 
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FOLLOW UP   OF HEARING  LOSS :  
During the follow up period  in a 51 DR-TB  patients,   3rd month 
follow up 27% (n-14) DR-TB  patients  had developed right sided  SNHL, 
20%(n-10)  DR-TB  patients  had developed left sided  SNHL . 
In the 6th month follow up period  DR-TB,  39%  (n-20)  patients  had 
developed right sided  SNHL  , 27% (n-14) ) DR-TB  patients  had 
developed left sided  SNHL  . 
 
 
Fig 16  FOLLOW UP  OF HEARING  LOSS 
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FOLLOW UP 
VISITS 
SIDE 
NO 
OF PATIENTS 
PERCENTAGE 
1 RIGHT 0 0 
 LEFT 0 0 
2 RIGHT 14 27% 
 LEFT 10 20% 
3 RIGHT 20 39% 
 LEFT 14 27% 
 
Table 3: NO OF PATIENTS DEVELOPED HEARING LOSS 
DURING FOLLOW UP  
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RELATIONSHIP BETWEEN ONSET OF OTOTOXICITY AND  
DURATION OF THE TREATMENT : 
Out of  51 DR-TB patients in this study, 22 DR-TB patients 
developed hearing loss.  Of these 77.27% (n-17) patients had developed 
hearing loss during the first three month of the intensive period ,  22.72% 
(n-5) DR-TB patients  developed  SNHL during the sixth month of  the 
DOTS PLUS regimen. 
Onest of 
Ototoxicity 
3rd month 4th month 5th month 6th month 
No of patients 
(n=22) 
17 (77.27%) 0 0 5(22.72%) 
Table 4. Onset Of Ototoxicity in MDR TB 
 
Fig 17.  FOLLOW UP  PERCENTAGE OF HEARING  LOSS 
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STATISTICAL SIGNIFICANCE OF OTOTOXICITY : 
 During  the follow up period of 51  DR-TB  patients audiometry 
results were analysed  by using ANNOVA TEST (analysis of variance) 
and Overall    p value is 0.002. This  p value is statistically 
SIGNIFICANT . Hence injection kanamycin produce definite ototoxicity 
among the DR-TB patients receiving  the  CATEGORY 4 regimen .   
 
 
Follow up P Value 
PTA All 0.002 
Right Ear 
1 and 2 0.24 
1 and 3 0.003 
2 and 3 1 
Left Ear 
All 0.003 
1 and 2 0.039 
1 and 3 0.003 
2 and 3 1 
Table 5 
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SYMPTOMS  ANALYSIS FOR OTOTOXICITY : 
 During the follow up   22 patients  developed hearing loss , 
36%(n-8) patients had vestibulo cochlear- symptoms  like  tinnitus , 
vertigo, hard of hearing, fullness of ear . Most  common symptom noticed 
in this study is tinnitus ( 75%) 
 64% (n-14) patients NOT aware of the symptoms associated with 
hearing loss . 
 
                   
 
Fig 18. Symptoms  Analysis For Ototoxicity 
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DIABETES AND DR-TB  WITH SENSOY NEURAL HEARING 
LOSS: 
Among 51 DR-TB patients , 10 patients found to be diabetic, in 
this sub group 7 paients developed SNHL  ( ototoxicity ) during the 
follow up period .     
  
Ototoxicity 
 
  
Yes No 
DM Yes 6 4 
 
No 16 25 
P value 0.295 Fisher's exact test 
                          Table . 6 
 
HIV  positive AND DR-TB patients WITH HEARING LOSS : 
Total of  51 patients , 5 patients were HIV – positive, 1 patient 
developed right sided mild hearing loss and left moderately severe hearing 
loss during the 3rd month follow up period.  
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NEPHROTOXICITY: 
Total of  51  DR - TB  patients, 4 patients (male-3, female-1) were 
found  elevated renal parameters above the normal  values. During the 
follow up period, 3rd month of the intensive phase 2%of patients noticed 
elevated urea and creatinine values above the normal range . 
Sixth month follow up period  8% patients (n-4)  had elevated 
blood urea levels above    the normal range . 4% (n-2) patients had 
elevated serum creatinine levels above the nomal range. 
 
 
Fig 19.Onset of Nephrotoxicity 
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No of visit Renal parameter No of patients % 
1 Urea 0 0% 
 Creatnine 1 2% 
2 Urea 1 2% 
 Creatnine 1 2% 
3 Urea 4 8% 
 Creatnine 2 4% 
Table .7 
 
STATISTICAL SIGNIFICANCE FOR NEPHROTOXICITY 
 
During the intensive period of CATEGORY IV  regimen, third and 
sixth month for urea level had significant p value  <0.0001  
 
 
Follow up P Value  
Urea All <0.0001 
 
1 and 2 0.055 
 
1 and 3 <0.0001 
 
2 and 3 0.1 
Table .7 
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During the intensive period of CATEGORY IV regimen, third and 
sixth month for serum creatinine  level had significant p value  0.023  
 
 
Follow up P Value 
Creatnine All 0.023 
 
1 and 2 1 
 
1 and 3 0.032 
 
2 and 3 0.09 
Table .8 
In this study overall statistically significant p values <0.05 obtained 
for 3rd and 6th  follow up period for both elevated blood urea and serum 
creatinine values.   
 
SYMPTOMS ANALYSIS FOR NEHROTOCITY : 
  Four  patients (male-3, female-1) were  elevated parameters are  
observed in this study.Most of the patients in this study noticed elevated 
renal parameters during  6th month follow up period. Patients are not 
aware of the symptoms of renal failure . 
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DIABETIS AND NEPHROTOXICITY: 
  10 diabetic patients are included in this study group , among them 
one patients had elevated blood urea and serum creatinine levels also 
ultrasonogram shows bilateral chronic medical renal disease at the 6th 
month of the intensive period . 
Statistically no significant p values ( 0.357)  obtained related to 
diabetes and nephrotoxicity among the DR-TB patients 
 
 
    Renal toxicity   
    Yes No 
DM Yes 1 9 
  No 1 40 
Table .9 
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OTOTOXICITY AND NEPHROTOXICITY : 
In this study group  total of 51 DR-TB  (n-51) patients, 2 patients 
had developed both ototoxicity and nephrotoxicity ,there is no satistically 
significant p values (1.000 )obtained  for both ototoxicity and 
nephrotoxicity. 
    Ren_toxi   
    Yes No 
oto_toxi Yes 1 28 
 
 No 1 21 
P value 1.000 Fisher's exact test 
 Table .10 
 
ANAEMIA : 
 Total of 51 DR-TB patients , 31 patients had Hb level less than 
11gms%,  among the 31 patients 17 patients developed SNHL 
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RESULTS : 
 In  this study total of 51 DR-TB patients were included ,41%(n-22) 
patients were developed significant  OTOTOXICITY ,2% (n-4)  patients 
had  NEHROTOXICITY,    2%(n-4)  patients  developed BOTH 
OTOTOXICITY AND NEPHROTOXICITY,  remaining 55%(n-30)  are 
ASYMPTOMATIC . 
 
Fig 20. Over all Percentage of Kanamycin Induced Toxicity 
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6. DISCUSSION 
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DISCUSSION: 
Injection kanamycin is the important  bactericidal  antibiotic drug 
used to treat the DR-TB patients  during the intensive phase of the 
CATEGORY IV regimen. According to weight basis  kanamycin is given 
as an intramuscular injection  given  for six days per week except Sunday 
dose. Kanamycin  is the drug well  known to produce ototoxicity and 
nephro toxicity. 
 Kanamycin induced ototoxicity is usually irreversible, because it  
destroys both inner and outer  hair cells in the cochlea. kanamycin 
induced ototoxicity is dose dependent manner, initially it affects the 
higher frequencies, later it affects lower frequencies and also involves the 
speech frequencies and  interfere with speech communication . 
Kanamycin  induce nephrotoxicity in a  duration dependent 
manner, it is concentrated in renal cortex and produces well documented 
nephrotoxicity. If kanamycin is used in patients with poor renal reserves it 
will potentiate nephrotoxicity  among them. 
In our study incidence of  injection kanamycin induced ototoxicity   
among  the DR-TB patients was  43.13%.  Prahlad duggal et al reported   
prevalence  of aminoglycoside  induced ototoxicity of  47%, out of which 
18.75% SNHL involving higher frequencies and 6.25% involving lower 
frequencies. 
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In our study  82% male , 18% females are included . Among these  
63.63%(n-14) males, 36.36% (n-8) female patients were developed SNHL 
during the six months follow up period.   In  our study 69%  (n-35) of the 
patients were in between 21 to 50 years of age group.   
  
In our study of 51 DR-TB patients 22 patients developed hearing 
loss. During the 3rd month follow up period out of 22 patients,  77.27% (n-
16) patients developed SNHL, 22.72 % (n-6) patients developed SNHL at 
the 6th month follow up period. Aasishkumar et al  conducted a study in  
govt surat medical college,  overall incidence of ototoxicity is 35%, of  
which during the 1st month follow up 62.85% , 2nd month follow up 
11.4% , 3rd month follow up 2.8% , 4th  5th and 6th month results  are  
8.57%,8.57%,5.71% respetively developed SNHL .  
Kanamycin induced ototoxicity initially involve higher 
frequencies. At that time most of the patients are not aware of the 
symptoms of ototoxicity, at this time if the patients was not diagnosed . 
Later it will involve lower and speech frequencies , patient may land up 
with  audiological symptoms,at this time  hearing loss will be permanent.  
Detection of the hearing loss in the later stages may  not be beneficial to 
the patient  by stopping the inj. kanamycin. Hence  strict audiogical 
evaluation is mandatory in DR-TB patients at the time of   initiation of  
CATEGORY IV regimen, also every month follow up period till 
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completion of inj.kanamycin, thereafter every three months till end of the 
treatment for early detection and prevention of ototoxicity .  
 
In our study  majority  64% (n-14) of patients were  unable to  
recognised  the symptoms of hearing loss, 36% (n-8) patients noticed 
symptoms of hearing loss   like tinnitus, hard of hearing, fullness of the 
ear and vertigo. In a symptomatic patients  most common symptom 
noticed is tinnitus (75%) , then hard of  hearing (16%) , least symptoms 
noticed were  fullness of the ear and vertigo.    
In our study  incidence of nephrotoxicity  was found in 2% , four   
patients  developed  statistically significant ( p values urea <0.0001, for 
serum creatinine 0.023) nephrotoxicity during the  follow up period  of 
CATEGORY IV regimen , none of them were aware of the symptoms 
associated with nephrotoxicity.   
In our study  simultaneous development of ototoxicity and 
nephrotoxicity found in 2% of  patients.  
In our study population 20% (n-10) patients were found to be 
diabetic, in this  group 70% (n-7) patients had  SNHL during the follow 
up period, among this group 86% of patients were male, 14% patients 
were female. None of these  patients had associated with nephrotoxicity. 
In our study diabetic patients with irrespective of glycemic control, none 
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of these patients were developed statistically significant symptomatic 
ototoxicity and nephrotoxicity.   
          In our study , 9.8% (n-5) of patients had HIV positive , in this group 
20% (n-1) patients developed otoxicity , none of them developed 
nephrotoxicity during the intensive phase period. Tashneem harris et al 
study shows 57% of HIV positive patients developed high frequency 
SNHL, when compared to HIV negative MDR-TB patients.  Co-existence 
of HIV positive status would not increase the nephrotoxicity and 
ototoxicity, which was statistically insignificant.  
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7.CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
CONCLUSION : 
1. In this prospective observational study, during the intensive phase 
of CATEGORY IV regimen  43.3% patients  developed 
statistically significant OTOTOXICITY , 2% patients developed  
NEPHROTOXICITY and 2% of patients developed BOTH 
OTOTOXICITY AND NEPHROTOXICITY.  
2. OTOTOXICITY-  63.63% patients   developed bilateral hearing 
loss  and 36.36% patients developed unilateral hearing loss. among 
the patients with ototoxicity  75%  patients   had  mild hearing loss, 
and  mostly  during first three months period  of the  intensive 
phase.  
3. In our study  64% patients with hearing loss are asymptomatic and 
36% patients noticed symptoms associated with hearing loss and 
the most common symptom being tinnitus (75%) . 
4 . In our  study 64 % of asymptomatic hearing loss cases were picked 
up by using pure tone audiometry. Early detection of the hearing loss 
among   these patients shall improve  adherence to the treatment. 
hence  pure tone audiometry to be  done as a pre treatment evaluation 
for all MDR-TB patients at the initiation of the treatment, every month 
for the first six months, then every three month till completion of the 
treatment.   
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TIRUNELVELI MEDICAL COLLEGE HOSPITAL 
                 DEPARTMENT OF THORACIC MEDICINE 
 
NAME:                                              AGE/SEX                           IP NO:                                
DATE: 
ADDRESS: 
 
CONTACT NO: 
1.Any previous history of Psychiatric Illness:      Yes/No 
2.Previous H/O hearing loss : Yes/No 
3.Willing for audiometry test : Yes/No 
4.Base line(first) audiometry date & result 
5.Followup audiometry at 3 months and 6 months  
                  DATE      AUDIOMETRY DONE            RESULTS 
1   
2   
3   
 
6.Any history of hearing problem during this period: Yes/No 
If yes – detailed h/o 
Tinnitus/HOH/Fullness of ear/Vertigo/Giddiness/Ataxia 
                FOLLOWUP        UREA    CREATININE 
1.   
2.   
3.   
 
Any H/O Oedema/Oliguria/Abdominal Pain : Yes/No 
S.No
PMDT 
NO
NAME AGE SEX PTA 1-R  PTA 1-L PTA2-R PTA2-L PTA3-R
PTA3-
L
URE
A1
CREA
TININ
E1
UREA
2
CREA
TINI
NE2
UREA3
CREA
TININ
E3
OUTCO
ME
OUTCOME  Hb DM HIV
PTA 
Symptom
s
1 Dharshini 22 F 23.3 30 24 26.4 24 26.4 16 0.8 18 0.9 24 0.9 3B U/L SNHL-L 12.4 NO NR NO
2 132/14 SHANMUGA SUNDARAM 34 M 18.3 18.3 18.3 18.3 20 20 22 0.7 26 0.9 28 0.8 1 Normal 13 NO NR
3 81/13 MAYANDI 33 M 20 21.6 76.6 64.6 76.6 64.6 26 1.1 28 1.4 47 1.6 2 & 4  B/L SNHL / RF10 NO NR YES
4 137/14 MASANAM 45 M 20 21.6 35 25.6 35 25.6 25 0.8 27 0.7 33 0.7 2 B/L SNHL 11.3 NO NR NO
5 104/14 PARAMASIVAM 33 M 23.3 20 23 18 15 15 16 0.9 24 0.8 26 0.8 1 Normal 8 NO REACTIVE
6 131/14 SUNDARAM 68 M 20.4 21 38 40 38 40 16 0.8 16 0.8 24 1 2 B/L SNHL 12 YES NR NO
7 130/14 MOHAMAD ASKAR 23 M 16.6 20 16.6 16.6 18 20.4 16 1 18 0.9 18 0.9 1 Normal 11 NO NR
8 128/14 JEBAKANI 22 F 21.6 20 18.4 18.4 18.8 20.4 16 0.8 24 1 22 1 1 Normal 8 NO REACTIVE
9 91/14 murugan 50 M 18.8 20 33.3 25 33.3 25 19 0.9 24 0.8 22 1 2 B/L SNHL 10 YES NR YES
10 57/14 SHAKEELA 30 F 20 18 18.6 24 20 21.4 20 0.7 18 0.8 24 1 1 Normal 11 YES NR
11 21/14 REJINA 49 F 20 20 23 20 23.3 23.3 20 0.8 24 0.8 32 0.8 1 Normal 10 NO REACTIVE
12 SIVARAJAN 40 M 20 20 18.4 20 20 21.4 22 0.8 28 0.6 42 0.8 4 Normal 8 NO NR
13 117/14 DURAISAMY 46 M 20 20 34 32.6 34 32.6 21 0.6 21 0.8 34 1 2 B/L SNHL 9 YES NR YES
14 GURUSAMY 38 M 18.3 20 21.4 20 20 20 24 0.9 22 1 24 0.8 1 Normal 10 NO REACTIVE
15 114/14 JAINSIRANI 35 F 20 20 22 22 58.3 51.6 25 0.8 26 0.9 29 1 2 B/L SNHL 10 NO NR YES
16 39/14 SUBBAIAH 50 M 21 21 90 85 90 85 28 0.8 40 1 40 1 2 B/L SNHL 9 NO NR YES
17 16/14 karupasamy 45 M 25 20 21 20 18 20 21 1 24 0.8 22 0.9 1 Normal 8.6 NO NR
18 BALAKRISHNAN 45 M 21.6 18.3 21.6 20 22 20 22 1 34 0.8 34 0.9 1 Normal 12 NO NR
19 69/14 RAMESH 25 M 18 21 55 20 55 20 22 1 32 1 28 1 3A U/L SNHL R 11 NO NR YES
20 SHANMUGA SUNDARAM 34 M 18.3 23.3 21.4 20 18 20.4 22 0.8 24 0.8 24 0.9 1 Normal 11 NO NR
21 73/14 HYDER ALI 51 M 18 20 20 21.3 46 60 28 0.9 42 1 44 1 2 B/L SNHL 10 NO NR YES
22 136/14 SUNDARA RAJAN 45 M 18 18 20 21.3 20 20 24 0.8 26 0.9 34 1 1 Normal 8 NO NR NO
23 112/14 SARASWATHI 51 F 20 20 21.3 24 38.6 33.3 24 0.8 34 0.9 34 0.9 2 B/L SNHL 10 YES NR
24 13/14 GANESAN 43 M 18 18 18.3 16.6 20 20 34 1 36 1 28 0.9 1 Normal 10 NO NR
25 86/14 AMBIGAI SELVI 23 F 15 16.6 18 18 18 18 19 0.9 21 0.9 18 0.9 1 Normal 9 NO NR NO
26 106/14/ SELVARAJ 40 M 23.3 18.3 20 20 21.3 18.3 25 0.8 25 0.8 28 1 1 Normal 11 NO NR
27 104/14 PARAMASIVAM 33 M 20.3 21 23.3 20 18.4 21 16 0.9 24 0.9 22 0.9 1 Normal 11 NO NR
28 152/14 LAXMANAN 67 M 21 21 20 18.3 16.6 18 18 0.7 24 0.9 80 2.1 4 RENAL 8 YES NR NO
29 319/14  S M RAHMAN 45 M 21.6 20 20 21 25 20 19 0.8 16 1.1 18 0.9 1 Normal 12 YES NR
30 133/14 MURUGAN 14 M 20 20 26.6 20 26.6 20 18 1.2 17 0.8 18 0.6 3A U/L SNHL R 10.4 NO NR NO
31 142/14 SUDALAI ANDI 68 M 20 20 21.6 23.3 20 25 22 0.8 18 0.7 24 1.1 1 Normal 12 NO NR
32 49/14 DEVARAJA SINGH 68 M 21.4 20 43.3 50 43.3 50 33 1.3 34 1.1 36 1 2 B/L SNHL 10.6 NO NR
33 114/14 BALASUBRAMANIYAN 34 M 22 18 20 20 28.3 21.4 34 0.7 28 0.9 34 0.7 3A U/L SNHL R 10 NO NR NO
34 67/14 MANI 36 M 18.3 18.6 19.2 18.3 18.3 18.3 16 0.6 24 0.8 18 0.8 1 Normal 11 YES NR
35 14/15 CHELLADURAI 55 M 21.6 20 24 21.4 28.3 21.6 18 0.9 18 0.9 21 0.9 3A U/L SNHL R 10 YES NR NO
36 100/14 MUTHIAH 60 M 18.3 21.6 18 20 18.3 21.6 19 0.9 18 0.9 18 0.8 1 Normal 12 NO NR
37 30/15 MUTHU RAKKU 43 M 18 19.6 33.3 60 33.3 60 22 0.9 34 0.8 24 0.9 2 B/L SNHL 10 NO REACTIVE YES
38 139/14 MUTHU PANDI 41 M 20 20 18 20 20 20.4 18 1.1 24 1.2 32 1.1 1 Normal 12 NO NR
39 147/14 MARIMUTHU 28 M 22.4 20 24 24 18 20 24 1 34 1.1 26 1.1 1 Normal 12 NO NR
40 SAROJA 50 F 18 20 21 24 25.6 26.6 18 0.9 22 0.9 24 1.1 2 B/L SNHL 10 NO NR NO
41 VELUSAMY 60 M 22 18 30 21.6 30 21.6 24 0.9 36 1 34 0.8 3A U/L SNHL R 10 NO NR NO
42 RAJASEKAR 53 M 18 20 28.3 23.3 28.3 23.3 34 1 28 0.9 36 1.1 3A U/L SNHL R 10 NO NR NO
43 70/13 BOOPATHI 53 M 18 20 21.4 20 21.6 20 24 0.6 28 0.8 22 1 1 NORMAL 12 NO NR
44 006/15 SANKARASAMY 54 M 24 18 38.3 38.3 38.3 38.3 24 0.8 18 0.6 34 1 2 B/L SNHL 8.6 NO NR NO
45 141/14 VELMURUGAN 31 M 22.3 18 22 18 20 21 24 0.9 36 0.8 26 1 1 Normal 11 NO NR
46 111/14 MOTCHAM 59 M 20 20 26.4 28 26.4 28 26 0.9 34 1 34 1.1 2 B/L SNHL 12 YES NR NO
47 19/14 RAVI 19 M 24 20 19 20 20 20 28 0.9 24 0.6 24 0.8 1 Normal 11 NO NR
48 103/14 JEYAPARVATHI 24 F 21 21 24 18 24 21 26 0.9 24 0.5 38 1.1 1 Normal
49 DHONI 11 M 21 21 25 38.3 25 38.3 18 0.9 24 1 32 1.1 3B U/L SNHL-L 12 NO NR NO
50 29/14 KARUPPAIAH 50 M 21 18 18 20 20 24 24 1 34 1 36 0.8 1 Normal 11 NO NR
51 75/14 RAJA 27 M 21 18.4 20 20 20 20 34 0.9 34 1.1 28 0.9 1 Normal 11 NO NR
